

PROZAC – 1986 DATA

DRUG	Patients	Suicidal Acts	Acts/ PEY	% Suicides & Suicidal Acts
Fluoxetine	6903	63	0.054	0.91%
Comparator	2310	15	0.043	0.65%

PROZAC – 1986 DATA

DRUG	Patients	Suicidal Acts	Acts/ PEY	% Suicides & Suicidal Acts
Fluoxetine	6903	63	0.054	0.91%
Comparator	2310	7	0.02	0.3%
Washout/Run In		4		
Other		4		

PROZAC – 1986 DATA

DRUG	Patients	Suicidal Acts	Acts/PEY	% Suicides & Suicidal Acts
Fluoxetine	6903	63		0.91%
Comparator	9213	15		0.16%

PROZAC – 1986 DATA

DRUG	Patients	Suicidal Acts	Acts/PEY	% Suicides & Suicidal Acts
Fluoxetine	6903	63	0.054	
Comparator	9213	15	0.002	

ABSOLUTE NUMBERS V PATIENT EXPOSURE YEARS

1. Dose Escalation

2. Crossover – Exposure Length ?

3. Breach of Randomization

Survival Analysis?

Breast Cancer – hard unavoidable endpoint

no expected dose-response relationship

Suicide

– hard avoidable endpoint

expected dose-response relationship

4. Agitation:

Drop-outs on sertraline 4.75%, on placebo 0.65%.

Committee on Safety of Medicines

Current Problems – 21

Precautions 6

Disinhibiting effects may be manifested in various ways. Suicide may be precipitated in patients who are depressed, and aggressive behaviour towards self and others may be precipitated. Extreme caution should therefore be used in prescribing benzodiazepines in patients with personality disorders.

PAXIL/SEROXAT 1990/1

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
Paroxetine	2,963	5	40	1.52%
Comparator	1151	3	12	1.30%
Placebo	554	2	6	1.44%

PAXIL/SEROXAT – 1990/1

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
Paroxetine	2,963	5	40	1.52%
Comparator	1151	3	12	1.30%
Placebo	554	0	3	0.54%
Washout/ Run In		2	2	

PAXIL/SEROXAT – 1990/1

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
Paroxetine	2,963	7	42	1.65%
Comparator	1151	3	12	1.30%
Placebo	554	0	1	0.18%
Washout/ Run In		2	2	

ZOLOFT/LUSTRAL – 1990/1

DRUG	Patients	Suicides	Suicidal Acts	Suicides & Suicidal Acts as %
Sertraline	2,053	2	7	0.44%
Comparator	595	0	1	0.17%
Placebo	786	0	5	0.64%

ZOLOFT/LUSTRAL – 1990/1

DRUG	Patients	Suicides	Suicidal Acts	Suicides & Suicidal Acts as %
Sertraline	2,053	2	7	0.44%
Comparator	595	0	1	0.17%
Placebo	786	0	2	0.25%
Washout/ Run In		0	3	

Sertraline – Suicidal Acts – IMB 1999

Number of suicidal events in clinical trials 252

Causality – Investigator – Yes it was Related - XY

Causality – Pfizer Review – Yes it was Related – XZ

Trials for anxiety, OCD, smoking cessation etc.

Broken down by dose etc

CELEXA

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
Citalopram	4,168	8	91	2.38%
Placebo	691	1	10	1.59%

EFEXOR

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
Venlafaxine	3082	7	36	1.40%
Placebo	739	1	2	0.41%

SSRI V PLACEBO

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
All SSRIs	13,693	23	186	1.53%
Comparator	3,681	5	24	0.79%
SSRI Placebo	3,140	5	21	0.82%

SSRI V PLACEBO

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
All SSRIs	13,693	23	186	1.53%
Comparator	3,681	5	24	0.79%
SSRI Placebo	3,140	2	16	0.57%
		3	5	

SSRI V PLACEBO

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
All SSRIs	13,693	23	186	1.53%
Comparator	3,681	5	24	0.79%
SSRI Placebo	3,140	2	14	0.51%
		3	5	

SSRIs in CHILDREN

Drug	No	Suicidal Act	%	Suicidal
Sertraline: depression	44	4	9	7
Sertraline: total	197	6	3	9
Placebo	85	1	1	1
Paroxetine:depression	93	5	5	10
Imipramine	95	1	1	2
Placebo	87	1	1	1

Benbow: There are a number of allegations that you made there, none of which are correct and in terms of whether we think Seroxat should be made available to children? Absolutely. 2% of children, 4% of adolescents will develop depression. The adolescents are at particular risk of suicide.

We have an obligation to make our medicines available to those patients at need. Adolescents are some of the patients who are most at need of anti-depressants. Suicide in adolescents is the third leading cause of death. ... We have a strong obligation to study our medicine in these patients to see if we can help them.

The vast majority of these patients did not have side effects significantly enough to withdraw from the treatment, the reality is that in this population depression is an extremely serious condition and in many cases leads to suicide.

Patient Information Leaflet

Current “well-meaning” wording increases the likelihood of suicide on SSRIs

Current “well-meaning” wording does harm to patients

PROZAC - NDA

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
Fluoxetine	1,427	1	12	0.91%
Placebo	370	1	0	0.27%

PROZAC- NDA

DRUG	Patients	Suicides	Suicidal Acts	% Suicides & Suicidal Acts
Fluoxetine	1,427	1	12	0.91%
Placebo	370	0	0	0.00%
		1	0	